S100B and Alzheimer disease: Ultimately, S100B's nonspecificity to astrocytes or neural tissue, and the readiness with which it is released into the blood in the setting of prevalent medical comorbidities, makes it less likely to be a useful addition to the AD biomarker arsenal.